U-M Rogel Cancer Center
Ann Arbor
About U-M Rogel Cancer Center
A secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer finds long-term hormone therapy does more harm than good for many men and calls for rethinking treatment guidelines based on a patient’s post-operative prostate-specific antigen (PSA) level.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Estimated revenue: $1K – $10K
- Last round: Grant (Sep 2019)
- Website: rogelcancercenter.org
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/u-m-rogel-cancer-center-760683 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.